A novel fibrinogen gamma-chain mutation, p.Cys165Arg, causes disruption of the γ165Cys–Bβ227Cys disulfide bond and ultimately leads to hypofibrinogenemia. Issue 172 (December 2018)

• Record Type: Journal Article
• Authors: Zhou, WeiJie; Luo, Meiling; Yan, Jie; Xiang, LiQun; Wei, AiQiu; Deng, Xuelian; Liao, Lin; Cheng, Peng; Deng, Donghong; Lin, Faquan
• Is Part Of: Thrombosis research. Issue 172(2018)
• Page Start: 128
• Page End: 134
• Publication Date: 2018-12
• Subjects: Congenital hypofibrinogenemia -- Fibrinogen -- Mutations -- Disulfide bond -- Thromboelastogram; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2018.10.018
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Background: Congenital hypofibrinogenemia is a type of hereditary disease characterized by impaired fibrinogen synthesis and/or secretion induced by mutations in the fibrinogen gene. Objectives: We investigated the phenotypes, genotypes, and pathogenesis of congenital hypofibrinogenemia in an affected family. Patients/methods: The proband had a risk of bleeding; therefore, conventional coagulation screening was performed for the proband and her family members. Mutation sites in all exons and flanking sequences of FGA, FGB, and FGG were identified, with matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) performed to indicate the expression of abnormal chains. The effect of the mutation sites on fibrinogen structure and function was predicted by molecular modeling, and purified plasma fibrinogen from the proband was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and scanning electron microscopy. Thromboelastography was applied to assess the risk of bleeding and clotting in the proband. Results: Fibrinogen levels in the proband were 1.21 g/L, 1.31 g/L, and 1.38 g/L according to Clauss assay, the prothrombin time method, and enzyme-linked immunosorbent assay, respectively. A novel heterozygous mutation (γCys165Arg), a heterozygous mutation (AαIle6Val), and two genetic polymorphisms (AαThr331Ala and BβArg478Lys) in fibrinogen were found in the proband, and MALDI-TOF MS indicated absence of the mutated chain in patient plasma. Additionally, the heterozygous mutation (γCys165Arg) displayed substitution of a nonpolar γ165Cys (low mass) with a positively charged Arg (high mass) along with a small fiber diameter and loose network structure. Conclusions: Fibrinogen γCys165Arg mutations cause damage to the interchain disulfide bonds of fibrinogen and hinder fibrinogen secretion, possibly explaining the pathological mechanism associated with congenital hypofibrinogenemia. Graphical abstract: (A) the disulfide bond of γ165Cys-Bβ227Cys of the fibrinogen molecule. (B) Wild type; (C) mutant type. The mutation (γCys165Arg) in fibrinogen leads to substitution of the nonpolar γ165Cys with a positively charged Arg, with this difference in charge potentially resulting in regional instability, thereby affecting secretion. Highlights: This study describes a case of congenital hypofibrinogenemia in China, revealing that a γCys165Arg mutation in fibrinogen induces damage to the interchain disulfide bond (γ165Cys Bβ227Cys) and results in dysfunctional fibrinogen secretion. Absence of the mutated chain in patient plasma confirmed the diagnosis of hypofibrinogenemia rather than hypodysfibrinogenemia, which was confirmed by MALDI-TOF MS. Reduced fibrinogen levels increase the risk of bleeding during the early and postpartum periods of pregnancy. Maintaining fibrinogen levels is crucial for minimizing hemorrhagic risk in pregnant patients with congenital hypofibrinogenemia.